NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · Delayed Price · USD
2.03
-0.32 (-13.62%)
At close: Jan 24, 2022 4:00 PM
1.88
-0.15 (-7.39%)
Pre-market:Jan 25, 2022 8:02 AM EST
Market Cap21.86M
Revenue (ttm)n/a
Net Income (ttm)-5.26M
Shares Out10.77M
EPS (ttm)-0.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,686
Openn/a
Previous Close2.35
Day's Range1.74 - 2.31
52-Week Range1.74 - 4.70
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About NRSN

NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Due to the complexity of neurodegenerative diseases, our strategy is to develop combined therapies targeting multiple pathways associated with these diseases. Our lead product candidate, PrimeC, is a novel extended-release oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Prim...

IndustryBiotechnology
IPO DateDec 9, 2021
CEOAlon Ben-Noon
Employees3
Stock ExchangeNASDAQ
Ticker SymbolNRSN
Full Company Profile

Financial Performance

Financial Statements

News

NeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study Results at Four International Conferences

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

2 weeks ago - PRNewsWire

NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team

CAMBRIDGE, Mass., Dec. 21, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

1 month ago - PRNewsWire

NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market

CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

1 month ago - PRNewsWire